Policy Developments - The National Healthcare Security Administration (NHSA) has announced a public solicitation for information on innovative medical consumables, including brain-machine interface technologies and surgical robots, to streamline the coding process for these products [2] Drug and Device Approvals - Fosun Pharma's subsidiary, Fosun Kary, has had its drug registration application for Brexucabtagene Autoleucel accepted by the National Medical Products Administration, aimed at treating relapsed or refractory B-cell acute lymphoblastic leukemia in adults [4] - Novogene's subsidiary has received medical device registration certificates for several neurodiagnostic reagents, which can assist in diagnosing Alzheimer's and Parkinson's diseases [5] Capital Market Activities - Hengrui Medicine has signed a licensing agreement for its innovative drug SHR-A1811, receiving an upfront payment of $18 million and potential milestone payments up to $1.093 billion, which will enhance its overseas market presence [7] - Yong'an Pharmaceutical plans to acquire a 49.20% stake in its subsidiary Ling'an Technology for 27 million yuan, aiming to strengthen control and reduce management costs [8] Industry Events - The NHSA hosted discussions with domestic and international investment institutions, emphasizing support for the high-quality development of innovative drugs and the implementation of policies to facilitate this growth [10] - Illumina has announced partnerships with several global pharmaceutical companies to develop companion diagnostics based on its TruSight Oncology genomic testing platform, focusing on KRAS gene mutations [11] Regulatory and Governance Updates - The former deputy director of the Henan Provincial Medical Security Bureau is under investigation for serious violations of discipline and law [13] - Shareholder Wang Xiaopeng of Huyou Pharmaceutical plans to reduce his stake by up to 3% due to personal financial needs [14] - Independent director Huang Zhengming of Qidi Pharmaceutical has resigned due to work reasons, which may affect the board's composition [15]

Mergers and Acquisitions - Huatian Technology is planning to acquire Huy Microelectronics, a subsidiary of its controlling shareholder, through a share issuance and cash payment, which is expected to constitute a related party transaction but not a major asset restructuring. The company's stock will be suspended from trading starting September 25 [1] - Dalong Real Estate's subsidiary intends to acquire 60% equity of Beijing Chengzhu Real Estate Development Co., Ltd. from Beijing Shunyi New Town Development Co., Ltd. to enhance project reserves and operational capabilities [2] - Yong'an Pharmaceutical plans to acquire 49.2% equity of its subsidiary Hubei Ling'an Technology Co., Ltd. from minority shareholders for 27 million yuan, aiming for full ownership [3] - Rongxin Culture's wholly-owned subsidiary intends to acquire 51% equity of Wuhan Youxue Baobei Book Co., Ltd. for 16.32 million yuan, which will be consolidated into the company's financial statements post-transaction [4] Shareholding Changes - Huyou Pharmaceutical's shareholder Wang Xiaopeng plans to reduce his stake by up to 3%, equivalent to a maximum of 12.708 million shares [5] - Beimo High-tech's shareholder Chen Jianfeng intends to reduce his stake by up to 2.49%, which amounts to a maximum of 8.2666 million shares [6] - Donghua Energy's controlling shareholder, Mansen Energy (Zhangjiagang), has increased its stake by 0.34%, acquiring 5.3093 million shares for approximately 45.6488 million yuan [7] Risk Matters - Zhangjiang Hi-Tech has announced a potential irrational speculation risk as its stock price has deviated significantly from industry peers and the Shanghai Composite Index, with a cumulative price increase of 20% over three consecutive trading days [8] - *ST Gaohong faces a risk of delisting as its stock price has been below 1 yuan for 18 consecutive trading days, with a potential delisting if the market capitalization remains below 500 million yuan for 20 consecutive trading days [9] - *ST Yatai's controlling shareholder's voting rights have decreased due to a forced sale of shares by a court, although this will not lead to a change in control or governance structure at this time [10]

（编辑 任世碧） 证券日报网讯 9月24日晚间，永安药业发布公告称，公司于2025年9月24日召开第七届董事会第九次临 时会议，审议通过了《关于收购控股子公司少数股东股权暨对外投资的议案》。基于战略规划与业务发 展需要，公司拟使用自有资金2，700万元收购控股子公司湖北凌安科技有限公司（简称"凌安科技"）少 数股东张勇、夏昌培、代亮合计持有的凌安科技49.20%股权，并签署《股权转让协议》。本次股权转 让完成后，公司将持有凌安科技100%股权，公司合并报表范围未发生变化。本次交易事项无需提交公 司股东会审议。 ...

Core Points - Yong'an Pharmaceutical Co., Ltd. announced adjustments to its business scope and board composition to enhance governance efficiency and adapt to operational needs [1][2] - The company plans to expand its business scope to include drug wholesale, import and export, and production and sales of pharmaceutical excipients, among other activities [1] - The board of directors will increase from 6 to 7 members, adding one employee representative director and one vice chairman, while the supervisory board will be abolished [1][2] Business Scope Adjustments - The previous business scope included the production and sales of APIs, food additives, and feed additives, as well as self-produced and sold products like ethylene oxide [1] - The new scope will include licensed projects such as drug wholesale and pharmaceutical excipients, along with general projects like chemical product production and technical services [1] Governance Enhancements - The company will revise parts of its articles of association, including increasing the number of board members and abolishing the supervisory board [1][2] - Eleven governance documents will be revised or established, including rules for shareholder meetings and board meetings, with three requiring shareholder approval [2]

格隆汇9月24日丨永安药业(002365.SZ)公布，公司拟使用自有资金2,700万元收购控股子公司湖北凌安科 技有限公司（简称"凌安科技"或"标的公司"）少数股东张勇、夏昌培、代亮合计持有的凌安科技49.20% 股权，并签署《股权转让协议》。本次股权转让完成后，公司将持有凌安科技100%股权，公司合并报 表范围未发生变化。 ...

Company Overview - Yong'an Pharmaceutical (SZ 002365) announced a temporary board meeting on September 24, 2025, to review the proposal for revising the "Board Audit Committee Work System" [1] - As of the report, Yong'an Pharmaceutical has a market capitalization of 5.2 billion yuan [1] Revenue Composition - For the first half of 2025, Yong'an Pharmaceutical's revenue composition is as follows: - Pharmaceutical manufacturing accounts for 64.14% - Health food accounts for 24.67% - Chemical manufacturing accounts for 10.88% - Other businesses account for 0.32% [1]

Core Viewpoint - The company plans to acquire 49.2% equity of Hubei Ling'an Technology Co., Ltd. from minority shareholders for 27 million yuan, aiming to achieve 100% ownership and enhance control over the subsidiary [1] Group 1: Acquisition Details - The acquisition involves minority shareholders Zhang Yong, Xia Changpei, and Dai Liang [1] - After the acquisition, the company will hold 100% equity of Ling'an Technology [1] Group 2: Business Transformation - Ling'an Technology successfully completed its business transformation in the first half of this year [1] - The company is now engaged in the production of monohydrate creatine, which is a key business segment for the company [1] Group 3: Strategic Objectives - The acquisition aims to strengthen the company's control over Ling'an Technology [1] - It is intended to reduce management costs and control risks [1] - The move is expected to accelerate Ling'an Technology's business expansion and market layout in the monohydrate creatine sector [1]

Core Viewpoint - The company plans to acquire a 49.20% stake in its subsidiary Hubei Ling'an Technology Co., Ltd. from minority shareholders for 27 million yuan, aiming to strengthen control and accelerate market positioning in its business areas [1] Group 1 - The acquisition will be funded by the company's own funds, ensuring that normal production and operations are not affected [1] - Following the completion of the transaction, Ling'an Technology will become a wholly-owned subsidiary of the company [1] - This move aligns with the company's overall strategic planning [1]

潜江永安药业股份有限公司 委托理财管理制度 第一章 总 则 第一条 为加强与规范潜江永安药业股份有限公司（以下简称"公司"）委 托理财业务的管理，有效控制风险，提高投资收益，维护公司及股东利益，根据 《中华人民共和国公司法》、《中华人民共和国证券法》、《深圳证券交易所股 票上市规则》、《深圳证券交易上市公司自律监管指引第1号——主板上市公司 规范运作》、《深圳证券交易所上市公司自律监管指引第7号—交易与关联交易》 等有关法律、法规和《潜江永安药业股份有限公司公司章程》（以下简称"《公 司章程》"）的有关规定，特制定本制度。 第二条 本制度所称委托理财是指在国家政策允许的情况下，公司及控股子 公司在控制投资风险的前提下，以提高资金使用效率、增加现金资产收益为原则， 委托银行、信托、证券、基金、期货、保险资产管理机构、金融资产投资公司、 私募基金管理人等专业理财机构对其财产进行投资和管理或者购买相关理财产 品的行为。 第三条 本制度适用于公司及控股子公司。公司控股子公司进行委托理财 须报经公司同意，未经审批不得进行任何理财活动。 第二章 委托理财管理原则 第四条 公司开展委托理财业务应当遵循审慎开展、依法合规、科 ...

潜江永安药业股份有限公司 证券投资、期货和衍生品交易管理制度 第一章 总 则 第一条 为规范潜江永安药业股份有限公司（以下简称"公司"）的证券投 资、期货和衍生品交易及相关信息披露行为，防范投资风险，强化风险控制，保 护投资者的权益和公司利益，根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《深圳证券交易所股票上市规则》、《深圳证券交易上市公司自律 监管指引第 1 号——主板上市公司规范运作》、《深圳证券交易所上市公司自律 监管指引第 7 号—交易与关联交易》等有关法律、法规和《潜江永安药业股份有 限公司公司章程》（以下简称"《公司章程》"）的有关规定，特制定本制度。 第二条 本制度所称的证券投资包括新股配售或者申购、证券回购、股票及 存托凭证投资、债券投资以及深圳证券交易所认定的其他投资行为。 本制度所述期货交易是指以期货合约或者标准化期权合约为交易标的的交 易活动。本制度所述衍生品交易是指期货交易以外的，以互换合约、远期合约和 非标准化期权合约及其组合为交易标的的交易活动。期货和衍生品的基础资产既 可以是证券、指数、利率、汇率、货币、商品等标的，也可以是上述标的的组合。 以下情形不适用本制度证券 ...